Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer.
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73600846" target="_blank" >RIV/61989592:15110/20:73600846 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/20:00115906 RIV/00216208:11120/20:43920073 RIV/00216208:11140/20:10410198 RIV/00216208:11150/20:10410198 a 5 dalších
Výsledek na webu
<a href="https://pubmed.ncbi.nlm.nih.gov/32234916/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/32234916/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.14182" target="_blank" >10.21873/anticanres.14182</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer.
Popis výsledku v původním jazyce
Aim: To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and methods: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. Results: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. Conclusion: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment.
Název v anglickém jazyce
Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer.
Popis výsledku anglicky
Aim: To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and methods: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. Results: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. Conclusion: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30203 - Respiratory systems
Návaznosti výsledku
Projekt
<a href="/cs/project/NV17-30748A" target="_blank" >NV17-30748A: Nová metoda kombinace funkčních zobrazovacích metod a nádorové genomiky pro neinvazivní fenotypizaci a sledování efektu léčby plicních karcinomů</a><br>
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2020
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
ANTICANCER RESEARCH
ISSN
0250-7005
e-ISSN
—
Svazek periodika
40
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
GR - Řecká republika
Počet stran výsledku
9
Strana od-do
2209-2217
Kód UT WoS článku
000522734400050
EID výsledku v databázi Scopus
2-s2.0-85082791859